Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that mycophenolate mofetil can enhance skin pigmentation in vitiligo models by activating the WNT signaling pathway and increasing melanin-related gene expression.

This review highlights that a comprehensive approach combining pharmacological, immunomodulatory, and regenerative interventions, including phototherapy enhanced with topical treatments and JAK inhibitors, appears effective and promising in the management of vitiligo by addressing its autoimmune and melanocyte-loss aspects.

Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.

This study found no protective effect of topical calcipotriol on hair loss in chemotherapy patients, and the authors propose the term "atrophic telogen effluvium" for this type of hair loss.

This study found that topical immunotherapy affects angiogenesis and immune cell ratios in the scalp, potentially offering insights into the mechanisms underlying alopecia areata.

Combining PRP with follicular transplantation improves vitiligo treatment better than follicular transplantation alone.

This study suggests that applying topical Tempol to the scalp before whole brain radiation may protect against radiation-induced alopecia and is safe and well-tolerated.

This study found that VMAT hair-sparing WBRT partially preserved scalp hair at four weeks post-treatment without compromising symptomatic disease control in the short term, but reduced hair loss did not improve quality of life.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

In this study, gene therapy using a VDR-expressing adenoviral vector promoted hair growth in Vdr-KO rats, suggesting its potential for treating alopecia associated with type II rickets.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

The researchers designed a Janus microneedle system for treating vitiligo, which targets the skin’s layers to regulate the immune response, promote melanocyte regeneration, and enhance pigment transfer, offering a new precise treatment approach for this condition.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This review reports that sonidegib and vismodegib, two Hedgehog inhibitors used for treating advanced basal cell carcinoma, have similar efficacy and safety profiles, but differ in pharmacokinetics, with sonidegib achieving peak concentration more rapidly and reaching steady state later than vismodegib.

This study reported that the novel topical serum REVIVV®, containing a blend of phytochemicals, significantly improved hair growth and reduced shedding in 150 participants with androgenetic alopecia after 8 weeks of use, while also being rated easy to use and prompting plans for continued use.

In this study, Mononuclear Cells provided site-specific protection against chemotherapy-induced alopecia in rats treated with Ara-C, but not with CTX or VP-16, while PRP showed no protective effect.

This review explores molecular targets for head and neck squamous cell carcinoma and discusses potential advancements in radiopharmaceuticals for targeted radionuclide therapy, reporting no new clinical results.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

The researchers reported that topical tofacitinib in mice increased hair follicles in the growth phase and boosted noggin and BMP4 mRNA expressions, compared to a vehicle and minoxidil.

This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.

This study found that vascular endothelial growth factor may protect hair follicle stem cells from androgen-induced apoptosis in androgenic alopecia patients via the PI3K/Akt pathway.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This study found that using a pH-sensitive layered double hydroxide nanocarrier to deliver etoposide significantly reduced liver toxicity and enhanced the drug’s effectiveness in targeting and suppressing non-small cell lung cancer.

This study found that long-term weekly administration of docetaxel is feasible at doses up to 45 mg/m² per week with acceptable toxicity, and suggests further evaluation with 40 mg/m² for phase II studies.

Combination therapies might work better for some vitiligo patients, but results vary.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.